AGTC News and Press, Applied Genetic Technologies Corporation From 11/09/21

Applied Genetic (NASDAQ:AGTC): FQ1 GAAP EPS of -$0.40 misses by $0.05. Press Release As of September 30, 2021, the Company's cash and cash equivalents totaled $90.5 million.  Management believes that these funds will be sufficient to allow the Company to generate data from its ...

-Company on track to provide multiple data readouts for XLRP and ACHM clinical programs in 2021 and 2022- -Company to host management update and webcast today at 8:00 a.m. ET- GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Co...

Applied Genetic (NASDAQ:AGTC) is scheduled to announce FQ1 earnings results on Tuesday, November 9th, before market open. The consensus EPS Estimate is -$0.35 (+41.7% Y/Y) and the consensus Revenue Estimate is $0.08M Over the last 3 months, EPS estimates have seen 1 upward revision and 0 down...

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal disea...

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal d...

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal d...

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited reti...

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited reti...

Gainers: ADVM +13.3%. SCPS +9.7%. BIDU +4.1%. AGTC +3.9%. APM +3.5%. Losers: HX -7.3%. NUVL -4.6%. RXRX -2.2%. FA -2.1%. FLYW -1.9%. For further details see: ADVM, SCPS, HX and NUVL among after hours movers

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited ret...